Clinical trial · Interventional
Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors
Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with kidney tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
| stereotactic radiosurgery | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Maximum tolerated dose of radiation
- timeFrame
- DLT is assessed at 4 and 8 weeks after radiotherapy
- measure
- Radiotherapy-associated toxicity
- timeFrame
- DLT is assessed at 4 and 8 weeks after radiotherapy
Secondary outcomes (5)
- measure
- Disease-free survival
- timeFrame
- follow-up will be done at 1 month, 6 12, 18 and 24 months post surgery
- measure
- Time to local progression
- timeFrame
- follow-up will be done at 1 month, 6 12, 18 and 24 months post surgery
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Radiologically confirmed renal tumor * At least 4 cm in greatest dimension * No clinically, radiologically, or pathologically involved lymph nodes * No distant metastases PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * Negative pregnancy test * Fertile patients must use effective contraception * Medically eligible for tumor resection * No major medical condition or psychiatric illness that would preclude study compliance * No active connective tissue disease, such as lupus or dermatomyositis * No active Crohn's disease or active ulcerative colitis PRIOR CONCURRENT THERAPY: * No prior chemotherapy * No prior abdominal or pelvic radiotherapy * No prior cryosurgery * No prior radiofrequency ablation
References
Publications (0)
Data not yet available